Therapeutic Radioligands Market, Global Outlook and Forecast 2023-2029
Report ID
39048
Publisher
Market Monitor Global
Published Date
03-Nov
Delivery Format
PDF
No of Report Page
103
Editor's Rating
US $3,250.00
US $4,225.00
US $4,875.00
  • Report Details 
    This research report provides a comprehensive analysis of the Therapeutic Radioligands market, focusing on the current trends, market dynamics, and future prospects. The report explores the global Therapeutic Radioligands market, including major regions such as North America, Europe, Asia-Pacific, and emerging markets. It also examines key factors driving the growth of Therapeutic Radioligands, challenges faced by the industry, and potential opportunities for market players.
The global Therapeutic Radioligands market has witnessed rapid growth in recent years, driven by increasing environmental concerns, government incentives, and advancements in technology. The Therapeutic Radioligands market presents opportunities for various stakeholders, including Solid Tumor, Non Hodgkin Lymphoma. Collaboration between the private sector and governments can accelerate the development of supportive policies, research and development efforts, and investment in Therapeutic Radioligands market. Additionally, the growing consumer demand present avenues for market expansion.
The global Therapeutic Radioligands market was valued at US$ 983.7 million in 2022 and is projected to reach US$ 4419.9 million by 2029, at a CAGR of 18.3% during the forecast period.
The key drivers of the radioimmunotherapy market is its potential to deliver highly targeted and precise treatment to cancer cells, sparing healthy tissues and reducing side effects compared to traditional radiation therapies. The ability of RIT to offer personalized treatment options based on specific cancer biomarkers further enhances its appeal in the field of precision medicine. However, the radioimmunotherapy market also faces challenges. One major challenge is the high cost associated with the development and production of radiopharmaceuticals, limiting access for some patients and healthcare systems. Additionally, navigating complex regulatory pathways for approval and reimbursement of RIT products can be time-consuming and resource-intensive for pharmaceutical companies. Furthermore, there may be limited awareness and acceptance of RIT among healthcare professionals and patients, leading to slower adoption rates and market penetration. Addressing these challenges requires continued research and investment in RIT technologies to improve efficacy and cost-effectiveness. Collaborations between pharmaceutical companies, research institutions, and healthcare organizations can facilitate knowledge-sharing and streamline the regulatory process.
Key Features:
The research report on the Therapeutic Radioligands market includes several key features to provide comprehensive insights and facilitate decision-making for stakeholders.
Executive Summary: The report provides overview of the key findings, market trends, and major insights of the Therapeutic Radioligands market.
Market Overview: The report provides a comprehensive overview of the Therapeutic Radioligands market, including its definition, historical development, and current market size. It covers market segmentation by Type (e.g., Beta-emitting, Targeted Alpha Therapy), region, and application, highlighting the key drivers, challenges, and opportunities within each segment.
Market Dynamics: The report analyses the market dynamics driving the growth and development of the Therapeutic Radioligands market. The report includes an assessment of government policies and regulations, technological advancements, consumer trends and preferences, infrastructure development, and industry collaborations. This analysis helps stakeholders understand the factors influencing the Therapeutic Radioligands market's trajectory.
Competitive Landscape: The report provides an in-depth analysis of the competitive landscape within the Therapeutic Radioligands market. It includes profiles of major market players, their market share, strategies, product portfolios, and recent developments. 
Market Segmentation and Forecast: The report segment the Therapeutic Radioligands market based on various parameters, such as by Type, region, and by Application. It provides market size and growth forecasts for each segment, supported by quantitative data and analysis. This helps stakeholders identify growth opportunities and make informed investment decisions.
Technological Trends: The report should highlight the key technological trends shaping the Therapeutic Radioligands market, such as advancements in Type One technology and emerging substitutes. It analyses the impact of these trends on market growth, adoption rates, and consumer preferences.
Market Challenges and Opportunities: The report identify and analyses the major challenges faced by the Therapeutic Radioligands market, such as technical bottleneck, cost limitations, and high entry barrier. It also highlights the opportunities for market growth, such as government incentives, emerging markets, and collaborations between stakeholders.
Regulatory and Policy Analysis: The report should assess the regulatory and policy landscape for Therapeutic Radioligands, including government incentives, emission standards, and infrastructure development plans. It should analyse the impact of these policies on market growth and provide insights into future regulatory developments.
Recommendations and Conclusion: The report conclude with actionable recommendations for stakeholders, such as Application One Consumer, policymakers, investors, and infrastructure providers. These recommendations should be based on the research findings and address key challenges and opportunities within the Therapeutic Radioligands market.
Supporting Data and Appendices: The report include supporting data, charts, and graphs to substantiate the analysis and findings. It also includes appendices with additional detailed information, such as data sources, survey questionnaires, and detailed market forecasts.
Market Segmentation
Therapeutic Radioligands market is split by Type and by Application. For the period 2018-2029, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of value.
Market segment by Type
    Beta-emitting
    Targeted Alpha Therapy
Market segment by Application
    Solid Tumor
    Non Hodgkin Lymphoma
Global Therapeutic Radioligands Market Segment Percentages, By Region and Country, 2022 (%)
    North America
        US
        Canada
        Mexico
    Europe
        Germany
        France
        U.K.
        Italy
        Russia
        Nordic Countries
        Benelux
        Rest of Europe
    Asia
        China
        Japan
        South Korea
        Southeast Asia
        India
        Rest of Asia
    South America
        Brazil
        Argentina
        Rest of South America
    Middle East & Africa
        Turkey
        Israel
        Saudi Arabia
        UAE
        Rest of Middle East & Africa
Major players covered
    Bayer
    Novartis
    Lantheus
    Aurobindo Pharma
    Mundipharma
    China Isotope & Radiation
    Curium Pharmaceuticals
    Gilead Sciences
    Clarity Pharmaceuticals
    Curasight
    Nordic Nanovector
    Philogen
    RadioMedix
    Telix Pharmaceuticals
    Orano Med
    Actinium Pharmaceuticals
    Y-mAbs Therapeutics
    Fusion Pharmaceuticals
Outline of Major Chapters:
Chapter 1: Introduces the definition of Therapeutic Radioligands, market overview.
Chapter 2: Global Therapeutic Radioligands market size in revenue.
Chapter 3: Detailed analysis of Therapeutic Radioligands company competitive landscape, revenue and market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Therapeutic Radioligands in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: The main points and conclusions of the report.
  • Table Of Content 
    1 Introduction to Research & Analysis Reports
    1.1 Therapeutic Radioligands Market Definition
    1.2 Market Segments
        1.2.1 Market by Type
        1.2.2 Market by Application
    1.3 Global Therapeutic Radioligands Market Overview
    1.4 Features & Benefits of This Report
    1.5 Methodology & Sources of Information
        1.5.1 Research Methodology
        1.5.2 Research Process
        1.5.3 Base Year
        1.5.4 Report Assumptions & Caveats
2 Global Therapeutic Radioligands Overall Market Size
    2.1 Global Therapeutic Radioligands Market Size: 2022 VS 2029
    2.2 Global Therapeutic Radioligands Market Size, Prospects & Forecasts: 2018-2029
    2.3 Key Market Trends, Opportunity, Drivers and Restraints
        2.3.1 Market Opportunities & Trends
        2.3.2 Market Drivers
        2.3.3 Market Restraints
3 Company Landscape
    3.1 Top Therapeutic Radioligands Players in Global Market
    3.2 Top Global Therapeutic Radioligands Companies Ranked by Revenue
    3.3 Global Therapeutic Radioligands Revenue by Companies
    3.4 Top 3 and Top 5 Therapeutic Radioligands Companies in Global Market, by Revenue in 2022
    3.5 Global Companies Therapeutic Radioligands Product Type
    3.6 Tier 1, Tier 2 and Tier 3 Therapeutic Radioligands Players in Global Market
        3.6.1 List of Global Tier 1 Therapeutic Radioligands Companies
        3.6.2 List of Global Tier 2 and Tier 3 Therapeutic Radioligands Companies
4 Market Sights by Product
    4.1 Overview
        4.1.1 By Type - Global Therapeutic Radioligands Market Size Markets, 2022 & 2029
        4.1.2 Beta-emitting
        4.1.3 Targeted Alpha Therapy
    4.2 By Type - Global Therapeutic Radioligands Revenue & Forecasts
        4.2.1 By Type - Global Therapeutic Radioligands Revenue, 2018-2023
        4.2.2 By Type - Global Therapeutic Radioligands Revenue, 2024-2029
        4.2.3 By Type - Global Therapeutic Radioligands Revenue Market Share, 2018-2029
5 Sights by Application
    5.1 Overview
        5.1.1 By Application - Global Therapeutic Radioligands Market Size, 2022 & 2029
        5.1.2 Solid Tumor
        5.1.3 Non Hodgkin Lymphoma
    5.2 By Application - Global Therapeutic Radioligands Revenue & Forecasts
        5.2.1 By Application - Global Therapeutic Radioligands Revenue, 2018-2023
        5.2.2 By Application - Global Therapeutic Radioligands Revenue, 2024-2029
        5.2.3 By Application - Global Therapeutic Radioligands Revenue Market Share, 2018-2029
6 Sights by Region
    6.1 By Region - Global Therapeutic Radioligands Market Size, 2022 & 2029
    6.2 By Region - Global Therapeutic Radioligands Revenue & Forecasts
        6.2.1 By Region - Global Therapeutic Radioligands Revenue, 2018-2023
        6.2.2 By Region - Global Therapeutic Radioligands Revenue, 2024-2029
        6.2.3 By Region - Global Therapeutic Radioligands Revenue Market Share, 2018-2029
    6.3 North America
        6.3.1 By Country - North America Therapeutic Radioligands Revenue, 2018-2029
        6.3.2 US Therapeutic Radioligands Market Size, 2018-2029
        6.3.3 Canada Therapeutic Radioligands Market Size, 2018-2029
        6.3.4 Mexico Therapeutic Radioligands Market Size, 2018-2029
    6.4 Europe
        6.4.1 By Country - Europe Therapeutic Radioligands Revenue, 2018-2029
        6.4.2 Germany Therapeutic Radioligands Market Size, 2018-2029
        6.4.3 France Therapeutic Radioligands Market Size, 2018-2029
        6.4.4 U.K. Therapeutic Radioligands Market Size, 2018-2029
        6.4.5 Italy Therapeutic Radioligands Market Size, 2018-2029
        6.4.6 Russia Therapeutic Radioligands Market Size, 2018-2029
        6.4.7 Nordic Countries Therapeutic Radioligands Market Size, 2018-2029
        6.4.8 Benelux Therapeutic Radioligands Market Size, 2018-2029
    6.5 Asia
        6.5.1 By Region - Asia Therapeutic Radioligands Revenue, 2018-2029
        6.5.2 China Therapeutic Radioligands Market Size, 2018-2029
        6.5.3 Japan Therapeutic Radioligands Market Size, 2018-2029
        6.5.4 South Korea Therapeutic Radioligands Market Size, 2018-2029
        6.5.5 Southeast Asia Therapeutic Radioligands Market Size, 2018-2029
        6.5.6 India Therapeutic Radioligands Market Size, 2018-2029
    6.6 South America
        6.6.1 By Country - South America Therapeutic Radioligands Revenue, 2018-2029
        6.6.2 Brazil Therapeutic Radioligands Market Size, 2018-2029
        6.6.3 Argentina Therapeutic Radioligands Market Size, 2018-2029
    6.7 Middle East & Africa
        6.7.1 By Country - Middle East & Africa Therapeutic Radioligands Revenue, 2018-2029
        6.7.2 Turkey Therapeutic Radioligands Market Size, 2018-2029
        6.7.3 Israel Therapeutic Radioligands Market Size, 2018-2029
        6.7.4 Saudi Arabia Therapeutic Radioligands Market Size, 2018-2029
        6.7.5 UAE Therapeutic Radioligands Market Size, 2018-2029
7 Therapeutic Radioligands Companies Profiles
    7.1 Bayer
        7.1.1 Bayer Company Summary
        7.1.2 Bayer Business Overview
        7.1.3 Bayer Therapeutic Radioligands Major Product Offerings
        7.1.4 Bayer Therapeutic Radioligands Revenue in Global Market (2018-2023)
        7.1.5 Bayer Key News & Latest Developments
    7.2 Novartis
        7.2.1 Novartis Company Summary
        7.2.2 Novartis Business Overview
        7.2.3 Novartis Therapeutic Radioligands Major Product Offerings
        7.2.4 Novartis Therapeutic Radioligands Revenue in Global Market (2018-2023)
        7.2.5 Novartis Key News & Latest Developments
    7.3 Lantheus
        7.3.1 Lantheus Company Summary
        7.3.2 Lantheus Business Overview
        7.3.3 Lantheus Therapeutic Radioligands Major Product Offerings
        7.3.4 Lantheus Therapeutic Radioligands Revenue in Global Market (2018-2023)
        7.3.5 Lantheus Key News & Latest Developments
    7.4 Aurobindo Pharma
        7.4.1 Aurobindo Pharma Company Summary
        7.4.2 Aurobindo Pharma Business Overview
        7.4.3 Aurobindo Pharma Therapeutic Radioligands Major Product Offerings
        7.4.4 Aurobindo Pharma Therapeutic Radioligands Revenue in Global Market (2018-2023)
        7.4.5 Aurobindo Pharma Key News & Latest Developments
    7.5 Mundipharma
        7.5.1 Mundipharma Company Summary
        7.5.2 Mundipharma Business Overview
        7.5.3 Mundipharma Therapeutic Radioligands Major Product Offerings
        7.5.4 Mundipharma Therapeutic Radioligands Revenue in Global Market (2018-2023)
        7.5.5 Mundipharma Key News & Latest Developments
    7.6 China Isotope & Radiation
        7.6.1 China Isotope & Radiation Company Summary
        7.6.2 China Isotope & Radiation Business Overview
        7.6.3 China Isotope & Radiation Therapeutic Radioligands Major Product Offerings
        7.6.4 China Isotope & Radiation Therapeutic Radioligands Revenue in Global Market (2018-2023)
        7.6.5 China Isotope & Radiation Key News & Latest Developments
    7.7 Curium Pharmaceuticals
        7.7.1 Curium Pharmaceuticals Company Summary
        7.7.2 Curium Pharmaceuticals Business Overview
        7.7.3 Curium Pharmaceuticals Therapeutic Radioligands Major Product Offerings
        7.7.4 Curium Pharmaceuticals Therapeutic Radioligands Revenue in Global Market (2018-2023)
        7.7.5 Curium Pharmaceuticals Key News & Latest Developments
    7.8 Gilead Sciences
        7.8.1 Gilead Sciences Company Summary
        7.8.2 Gilead Sciences Business Overview
        7.8.3 Gilead Sciences Therapeutic Radioligands Major Product Offerings
        7.8.4 Gilead Sciences Therapeutic Radioligands Revenue in Global Market (2018-2023)
        7.8.5 Gilead Sciences Key News & Latest Developments
    7.9 Clarity Pharmaceuticals
        7.9.1 Clarity Pharmaceuticals Company Summary
        7.9.2 Clarity Pharmaceuticals Business Overview
        7.9.3 Clarity Pharmaceuticals Therapeutic Radioligands Major Product Offerings
        7.9.4 Clarity Pharmaceuticals Therapeutic Radioligands Revenue in Global Market (2018-2023)
        7.9.5 Clarity Pharmaceuticals Key News & Latest Developments
    7.10 Curasight
        7.10.1 Curasight Company Summary
        7.10.2 Curasight Business Overview
        7.10.3 Curasight Therapeutic Radioligands Major Product Offerings
        7.10.4 Curasight Therapeutic Radioligands Revenue in Global Market (2018-2023)
        7.10.5 Curasight Key News & Latest Developments
    7.11 Nordic Nanovector
        7.11.1 Nordic Nanovector Company Summary
        7.11.2 Nordic Nanovector Business Overview
        7.11.3 Nordic Nanovector Therapeutic Radioligands Major Product Offerings
        7.11.4 Nordic Nanovector Therapeutic Radioligands Revenue in Global Market (2018-2023)
        7.11.5 Nordic Nanovector Key News & Latest Developments
    7.12 Philogen
        7.12.1 Philogen Company Summary
        7.12.2 Philogen Business Overview
        7.12.3 Philogen Therapeutic Radioligands Major Product Offerings
        7.12.4 Philogen Therapeutic Radioligands Revenue in Global Market (2018-2023)
        7.12.5 Philogen Key News & Latest Developments
    7.13 RadioMedix
        7.13.1 RadioMedix Company Summary
        7.13.2 RadioMedix Business Overview
        7.13.3 RadioMedix Therapeutic Radioligands Major Product Offerings
        7.13.4 RadioMedix Therapeutic Radioligands Revenue in Global Market (2018-2023)
        7.13.5 RadioMedix Key News & Latest Developments
    7.14 Telix Pharmaceuticals
        7.14.1 Telix Pharmaceuticals Company Summary
        7.14.2 Telix Pharmaceuticals Business Overview
        7.14.3 Telix Pharmaceuticals Therapeutic Radioligands Major Product Offerings
        7.14.4 Telix Pharmaceuticals Therapeutic Radioligands Revenue in Global Market (2018-2023)
        7.14.5 Telix Pharmaceuticals Key News & Latest Developments
    7.15 Orano Med
        7.15.1 Orano Med Company Summary
        7.15.2 Orano Med Business Overview
        7.15.3 Orano Med Therapeutic Radioligands Major Product Offerings
        7.15.4 Orano Med Therapeutic Radioligands Revenue in Global Market (2018-2023)
        7.15.5 Orano Med Key News & Latest Developments
    7.16 Actinium Pharmaceuticals
        7.16.1 Actinium Pharmaceuticals Company Summary
        7.16.2 Actinium Pharmaceuticals Business Overview
        7.16.3 Actinium Pharmaceuticals Therapeutic Radioligands Major Product Offerings
        7.16.4 Actinium Pharmaceuticals Therapeutic Radioligands Revenue in Global Market (2018-2023)
        7.16.5 Actinium Pharmaceuticals Key News & Latest Developments
    7.17 Y-mAbs Therapeutics
        7.17.1 Y-mAbs Therapeutics Company Summary
        7.17.2 Y-mAbs Therapeutics Business Overview
        7.17.3 Y-mAbs Therapeutics Therapeutic Radioligands Major Product Offerings
        7.17.4 Y-mAbs Therapeutics Therapeutic Radioligands Revenue in Global Market (2018-2023)
        7.17.5 Y-mAbs Therapeutics Key News & Latest Developments
    7.18 Fusion Pharmaceuticals
        7.18.1 Fusion Pharmaceuticals Company Summary
        7.18.2 Fusion Pharmaceuticals Business Overview
        7.18.3 Fusion Pharmaceuticals Therapeutic Radioligands Major Product Offerings
        7.18.4 Fusion Pharmaceuticals Therapeutic Radioligands Revenue in Global Market (2018-2023)
        7.18.5 Fusion Pharmaceuticals Key News & Latest Developments
8 Conclusion
9 Appendix
    9.1 Note
    9.2 Examples of Clients
    9.3 Disclaimer
  • Inquiry Before Buying

    Inquiry Before Buying

    Your personal details will remain secure and confidential - Privacy Policy

    WHY CHOOSE US

    Easy Access and Express Report Delivery Service
    Discover Business Growth Opportunities
    More than 10 Years Experience Employee Support
    In-depth and Comprehensive Analysis
    100+ Client Queries Handled Everyday
  • Request Sample

    Request For Sample

    Your personal details will remain secure and confidential - Privacy Policy

    WHY CHOOSE US

    Easy Access and Express Report Delivery Service
    Discover Business Growth Opportunities
    More than 10 Years Experience Employee Support
    In-depth and Comprehensive Analysis
    100+ Client Queries Handled Everyday


Our Trusted Clients
cooper.fr
koronos
waldenmedical
unioncomm.co.kr
technopathclinicaldiagnostics
toho-titanium.co.jp
straubmedical
sew-eurodrive.de
medurifarms
naperol
nvent
network.ae
petronas
saeedghodran
polyworldsys
seedplanning.co.jp
kraton
ipms.fraunhofer.de
infanttech
httpswww.castel-freres
hintoninfo
hexcel
freightways.co.nz
excelitas
Acco
aspet
brand
bmc
elevate
europ-assistance


GET IN TOUCH
Phone: +1 (415) 315-9432
Phone: +91 86698 89536
Email: inquiry@wiredrelease.com
SHORT NAVIGATION
connect with us